Novo S.A.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2010-07-15
Share capital
1,333,000.00 PLN
Activity description

Novo is a pharmaceutical wholesaler and supplier offering a wide range of services for the pharmaceutical industry and healthcare sector. The company ensures stable distribution of pharmaceutical products from manufacturers to patients, adhering to Good Distribution Practice (GDP) standards. Novo operates in six provinces, providing pharmaceutical and medical products with a commitment to maintaining stock levels and stable pricing policies.

Registered address
ul. Mikołowska 232, 43-100 Tychy, Poland
Website
Email
Phone
Electronic delivery address
AE:PL-62443-86231-UATTH-27

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$507,553
Profit allocationDividend and reserves
Loans and borrowings$0
Capital expenditure$4,646
Foreign sales0.56% of revenue ($1,179,158)
Revenue structureTowary – hurt

Filing timeliness

Financial statements were filed on time, on average 117 days early. All were audited by a statutory auditor.

  • 202516/04/2026
  • 202426/03/2025
  • 202315/04/2024
  • 202205/04/2023
  • 202111/04/2022
  • 202018/03/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Wholesale of pharmaceutical goods31 / 1,137
Top 2.7%
Division · Wholesale trade142 / 20,054
Top <1%
City · Tychy6 / 1,242
Top <1%
Voivodeship · Śląskie111 / 33,177
Top <1%
Country · Poland1,042 / 297,266
Top <1%

Results vs industry

Revenue
This companyUSD 209.52mMedianUSD 1.08mAverageUSD 22.53m
Net profit
This companyUSD 2.18mMedianUSD 38.88kAverageUSD 884.46k
Operating costs
This companyUSD 206.34mMedianUSD 962.19kAverageUSD 21.20m
Assets
This companyUSD 54.31mMedianUSD 609.97kAverageUSD 11.91m

Authorized Representatives

Dariusz Gambuś age 62 – Vice President of the Management Board
Janusz Nahorniak age 68 – President of the Management Board

Manner of representation

Joint action by two members of the management board is required to make declarations of will on behalf of the company.

Supervisory board

Adrian Dzwonek age 39 – Supervisory Board Member
Bogdan Kamiński age 61 – Supervisory Board Member
Katarzyna Nahorniak age 30 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2010-07-30.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$407.9K
Buildings and premises
$3M
Investment property
$7,860

Public aid

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$515
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$20,001

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Przedsiębiorstwo Dystrybucji Farmaceutycznej Slawex sp. z o.o.
Hurtap S.A.
Centrala Farmaceutyczna Cefarm S.A.
Medi&More sp. z o.o.
Abbvie sp. z o.o.
Natur Produkt Zdrovit sp. z o.o.
Przedsiębiorstwo Zaopatrzenia Aptek Multi Pharme S.A.
Producencka Centrala Farmaceutyczna Procefar sp. z o.o.
Tramco sp. z o.o.
Lubfarm S.A.

Change history

DateEvent
2023-08-29PKD change
2023-02-15Address change
2015-09-02PKD change
2011-11-18Share capital increase
2010-07-15Entered in the register

FAQ

Last updated: 2026-07-17